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Oxaliplatin, unlike other platinum derivatives, does not result in significant renal 
impairment or ototoxicity, and it has only mild hematological and gastrointestinal 
toxicity. On the other hand the limiting side effect is its neurotoxicity that acts as bas-
es for a neuropathic syndrome. A tangled panel of symptoms may be disabling for 
these patients, adversely affecting activities of daily living and thereby quality of life. 
In a rat model of painful oxaliplatin-induced neuropathy, we are describing a pat-
tern of molecular and morphological alterations of both the peripheral and the cen-
tral nervous system. Among them an important activation of the glial component has 
been evidenced. Alpha7 nAChR is widely expressed throughout the CNS. It has been 
described in neurons, microglia and astrocytes, where it seems to play a modulatory 
role. Moreover, alpha7 nAChR stimulation induces antihyperalgesic and neuroprotec-
tive effects in trauma-induced neuropathy. 
Aimed to study the pathophysiological mechanism of the chemotherapy-dependent 
neuropathy, the role of the alpha7 nAChR was investigated in the rat model of oxal-
iplatin-induced neuropathy (2.4 mgkg-1 intraperitoneally, daily injected for 21 days).
At day 21th, when neuropathic pain is well established, alpha7 nAChR protein 
level expression was dramatically decreased both in the peripheral and in the central 
nervous system. The repeated treatment with the alpha7 nAChR agonist PNU-282987 
(30 mgkg-1 p. os, daily administered for 21 days, starting from the first oxaliplatin 
injection) was able to prevent mechanical hyperalgesia (evaluated by Paw pressure 
test). Moreover, mechanical (evaluated by Von Frey test) and thermal allodynia (eval-
uated by Cold Plate test) were significantly reduced. Repeated treatment with PNU-
282987 was also able to improve motor coordination (evaluated by Rota-rod test).
Western blot analysis revealed that the repeated treatment with the agonist pre-
vented the decrease of alpha7 protein level in a significative manner. Further ex vivo 
analysis of the nervous system showed a PNU-282987 neuroprotective effect: in mor-
phological terms, in the dorsal root ganglia, and in the peripheral nerve and in the 
spinal cord as indicated by molecular parameters. 
These results strongly suggest the pivotal role of alpha7 nAChR in the neuropro-
tection during neuropathy.
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